Skip to main content
. 2023 Feb 22;2023:9511499. doi: 10.1155/2023/9511499

Table 2.

Indication for laboratory assessment of DOAC level.

Overall N = 119 Apixaban n = 62 Rivaroxaban n = 57
Urgent/emergent procedure 38 (32) 28 (45) 10 (18)
Acute kidney injury 17 (14) 10 (16) 7 (12)
Bleed event on DOAC 11 (9) 5 (8) 6 (11)
Recurrent VTE on DOAC 10 (8) 5 (8) 5 (9)
Thrombophilia 9 (8) 0 (0) 9 (16)
Other 7 (6) 2 (3) 5 (9)
History of recurrent VTE pre-DOAC 6 (5) 0 (0) 6 (11)
High body weight 16 (13) 10 (16) 6 (11)
Low body weight 5 (4) 2 (3) 3 (5)